"We are able to identify predictive immune biomarkers of atopic dermatitis using a noninvasive method," the investigator said.
News from the FDA/CDC
Approval was based on data from two randomized, controlled trials, PRIME and PRIME2, comparing dupilumab with placebo in 311 adults with...
Hand eczema is one of the most common skin disorders and is the most common occupational skin disease, the authors wrote.
Daily emollient use was associated with a 29% lower risk of cumulative AD at 1 year in comparison with the control intervention.
Tralokinumab earns EU recommendation to expand age range for atopic dermatitis to include adolescents
In December 2021, tralokinumab was approved for adults with moderate to severe AD in the United States, where it is marketed as Adbry.
Narrowband UVB (NB-UVB) phototherapy remains a safe and efficacious nonpharmacologic treatment for dermatologic conditions in older and younger...
The study evaluated a foam formulation of roflumilast, a PDE4 inhibitor that is available for topical use in a cream formulation that was recently...
Although various treatments are used off label for many patients with moderate to severe PN, disease control is inadequate, and the patients are “...
Although it previously was thought that atopic dermatitis (AD) and allergic contact dermatitis (ACD) could not coexist due to their polarized...
The labels of JAK inhibitors include a boxed warning describing an increased risk of “serious heart-related events such as heart attack or stroke...
From the Journals
“These results ... support the use of abrocitinib in patients who might have received biologic therapy prior.”